Aug 29, 2011 08:20 EDT nxt2b (Nexttobe AB) an investment company owned by Bengt Ågerup, has today signed an agreement with a group of shareholders in Olink AB to purchase 49 % of the outstanding shares in the company. The intention is to accelerate the growth and value creation of the company by injecting knowledge, experience and financial strength to complement Olink’s unique product and technology position.

Apr 27, 2011 09:21 EDT Proseek™ is a user friendly open assay development reagent kit for the detection and quantification of proteins in serum or plasma samples. It offers the same level of performance as ELISA, but uses extremely low sample volumes; only1 µl is required for each reaction thus enabling the scientist to study precious bio-banked materials and plasma from small laboratory animals.

Mar 08, 2011 07:30 EST Olink Bioscience now offers a new research service, Plasma Biomarker Discovery Service. Using the multiplexed PLA® immunoassay platform, up to 74 potential cancer biomarkers are analyzed with high sensitivity in precious biobanked plasma samples, in no more than 2 µl of sample. This enables identification of novel biomarkers and contributies to the understanding of human cancer.

Nov 12, 2009 03:37 EST Olink Bioscience has signed an agreement with Space Import-Export s.r.l for distribution of the Duolink® product line in Italy. This is a further step in the process to penetrate the European market.

Nov 09, 2009 05:54 EST Olink Bioscience a Sweden based biotechnology company has entered into a distribution agreement with Axxora LLC for distribution of Olink Bioscience product line Duolink® in the North American market. Axxora, a major life science research distributor in San Diego, USA, will handle distribution and service of Olink Bioscience products.

Sep 14, 2009 02:48 EDT Olink Bioscience and its sister company Olink Genomics is participating in the project “Companion Diagnostics Initiative” which is financed by Vinnova and aims to develop improved cancer diagnostics to increase survival rate of patients with colorectal cancer.